<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chemotherapy with FOLFOX, which is a combination of <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU)/leucovorin (LV) and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, has been used worldwide for the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to examine the candidates for predictors of the efficacy of the FOLFOX treatment regimen in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, using formalin-fixed paraffin-embedded specimens </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of thymidylate synthase (TS), <z:chebi fb="0" ids="17748">thymidine</z:chebi> phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), <z:chebi fb="0" ids="30839">orotate</z:chebi> phosphoribosyltransferase (OPRT) and excision repair cross-complementing 1 (ERCC1) in 70 primary lesions and 30 liver metastatic lesions of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients, using laser capture microdissection and real-time PCR methods </plain></SENT>
<SENT sid="3" pm="."><plain>We then analyzed the correlation between their expression in <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> and those in corresponding liver metastatic lesions (n=30) and the relationship between their expression in the <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> and the efficacy of mFOLFOX6 in 45 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The gene expression in <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> positively correlated with those in corresponding liver metastatic lesions </plain></SENT>
<SENT sid="5" pm="."><plain>The profiles of gene expression of <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> strongly correlated with those of synchronous liver metastatic lesions compared to that of metachronous liver metastatic lesions </plain></SENT>
<SENT sid="6" pm="."><plain>TS and TP <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in the patients with complete response, partial response or stable disease (n=34) were significantly lower compared to those in the patients with progressive disease (n=11) (p=0.017 and p=0.04, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Our results indicated that TS and TP <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression profiles in <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesions</z:e> are sufficient to estimate the <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression profiles in synchronous liver metastatic lesions compared to metachronous liver metastatic lesions </plain></SENT>
<SENT sid="8" pm="."><plain>Additionally, these profiles may be useful predictors in the identification of eligible <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> for FOLFOX treatment </plain></SENT>
</text></document>